Horacio Nastri

Horacio Nastri

Company: Incyte Corporation

Job title: Executive Director


Panel Discussion: Exploring Strategies to Overcome On-Target Off-Tumour Toxicities 2:05 pm

• Examine challenges with on-target off-tumour toxicities • Discuss methods to override on-target off-tumour toxicities • What are firms currently doing to tackle key challenges?Read more

day: Day One

Panel Discussion: Contrasting Bispecific Therapeutics & CAR-T Approaches 9:25 am

• Evaluate off-the-shelf verses personalized therapies • Understand how contrasting bispecific approaches manage safety for on target off tumor toxicities • Investigate differences in solid and liquid tumour targeting • Examine whether discussed therapeutics are to be considered cures or therapies bridging the gap for the next breakthrough?Read more

Panel Discussion: Demonstrating the Superiority of Bispecifics in Immuno-Oncology Indications in Comparison with Antibody Combinations 9:50 am

Exploring the pros and cons of pursuing bispecific constructs in comparison with combination approaches Examining the potential novel biologies that are opened up by utilizing multispecific approaches Identifying scenarios in which bispecifics can add the most value and show significant superiority over alternative approachesRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.